ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.

1. Freeman EJ, Ferrario CM, Tallant EA: Angiotensin differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertens 1995;8:1105-1111.

2. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J: Biochemical assessment of myocardial fibrosisin hypertensive heart disease. Hypertension 2001;38:1222-1226.

3. Schilfrin EL: Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002;113:409-418.

4. Li JS, Shnrifi AM, Schiffrin EL: Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. J Cardiovasc PharmacoI1997;30:75-83.

5. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I, Diez J: Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999;17:107-114.

6. Bohlen HG: Localization of vascular resistance changes during hypertension. Hypertension 1986;8:181-183.

7. Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol Rev 1990;70:921-961.

8. Schilfrin EL: Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension 1992;19(2 Suppl): II1-II9.

9. Hasdai D, Gibbons RI, Holmes DR Jr, Higano ST, Lerman A: Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997;96:3390-3395.

10. Ruilope LM, Alcazar 1M, Rodicio JL: Renal consequences of arterial hypertension. J Hypertens 1992; IO (Suppl): S85-S90. II.

11. С остальными литературными источниками (11-31) можно ознакомиться – cardio.nauka@yandex.ru